Eleven Biotherapeutics, Inc. (EBIO) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $1.58, up from yesterday’s close by 13.67%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Eleven Biotherapeutics, Inc. (EBIO) currently trades with a market capitalization of $52.85 Million. That value represents a market adjusting for revenues that have been falling by -100.00 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of $0 over the past twelve months. Generally speaking, earnings are expected to hold steady in coming quarters. Analysts are forecasting earnings of -$0.13 on a per share basis this quarter. Perhaps, that suggests something about why 3.28% of the outstanding share supply is held by institutional investors.
We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Eleven Biotherapeutics, Inc. recorded a 52-week high of $2.01. It is now trading 0.43% off that level. The stock is trading $1.08 its 50-day moving average by -0.5%. The stock carved out a 52-week low down at $0.62.
In recent action, Eleven Biotherapeutics, Inc. (EBIO) has made a move of +47.66% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 13.41, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 4.91% with $27.33 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of EBIO.